Get the Stockscreener App
2.35
0.42%
-0.010
After Hours:
2.34
-0.01
-0.43%
Aytu Biopharma Inc stock is traded at $2.35, with a volume of 21,111.
It is down -0.42% in the last 24 hours and down -6.00% over the past month.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.
See More
Previous Close:
$2.36
Open:
$2.37
24h Volume:
21,111
Relative Volume:
1.00
Market Cap:
$14.09M
Revenue:
$93.76M
Net Income/Loss:
$-13.68M
P/E Ratio:
-0.2288
EPS:
-10.27
Net Cash Flow:
$8.77M
1W Performance:
-1.26%
1M Performance:
-6.00%
6M Performance:
-22.70%
1Y Performance:
-12.96%
1-Day Range:
$2.34
$2.43
1-Week Range:
$2.295
$2.85
52-Week Range:
$2.20
$3.50
Aytu Biopharma Inc Stock (AYTU) Company Profile
Name
Aytu Biopharma Inc
Sector
Phone
(720) 437-6580
Address
7900 E. UNION AVENUE, DENVER
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-29-20 | Initiated | H.C. Wainwright | Buy |
Aytu Biopharma Inc Stock (AYTU) Latest News
Aytu BioPharma Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Earnings call: Aytu BioPharma reports turnaround with focus on ADHD By Investing.com - Investing.com Australia
When Will Aytu BioPharma, Inc. (NASDAQ:AYTU) Turn A Profit? - Simply Wall St
Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results - AccessWire
Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results - StockTitan
Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024 - AccessWire
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha
Balance Sheet Insights: Atyr Pharma Inc (ATYR)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Anterix (NASDAQ:ATEX) Sees Unusually-High Trading Volume - Defense World
Atlantica Sustainable Infrastructure (NASDAQ:AY) Now Covered by StockNews.com - Defense World
Applied Therapeutics Stock Soars As FDA Scraps Panel Meeting For Its Inherited Metabolic Disorder Drug - Benzinga
Altamira Therapeutics announces pricing of $12M offering - TipRanks
Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024 - StockTitan
Jupiter Asset Management Ltd. Makes New Investment in Anterix Inc. (NASDAQ:ATEX) - Defense World
Analysts Expect Breakeven For Aytu BioPharma, Inc. (NASDAQ:AYTU) Before Long - Yahoo Finance
Comparing Sanofi (NASDAQ:SNY) & Aytu BioPharma (NASDAQ:AYTU) - Defense World
Alaska Air clears hurdle in proposed merger with Hawaiian Airlines - Head Topics
Aytu BioPharma, Inc. (NASDAQ:AYTU) Short Interest Update - Defense World
Aytu BioPharma (NASDAQ:AYTU) Share Price Crosses Below 50 Day Moving Average of $2.77 - Defense World
Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024 - AccessWire
Aytu BioPharma sells consumer health unit to focus on Rx products - Investing.com India
Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations - AccessWire
Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations - StockTitan
Aytu BioPharma (NASDAQ:AYTU) & SIGA Technologies (NASDAQ:SIGA) Critical Analysis - American Banking and Market News
Aytu BioPharma (NASDAQ:AYTU) vs. SIGA Technologies (NASDAQ:SIGA) Financial Survey - Defense World
Aytu BioPharma (NASDAQ:AYTU) Share Price Crosses Below 50 Day Moving Average of $2.89 - Defense World
Aytu BioPharma (NASDAQ:AYTU) Share Price Passes Below 50 Day Moving Average of $2.95 - Defense World
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire Inc.
Aytu BioPharma Inc. (AYTU) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo News Australia
Aytu BioPharma Shareholders Approve All Proposals at Annual Meeting - Investing.com India
Aytu BioPharma Shareholders Approve All Proposals at Annual Meeting By Investing.com - Investing.com Australia
Aytu BioPharma Shareholders Approve All Proposals at Annual Meeting By Investing.com - Investing.com South Africa
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
Evofem Biosciences revises preferred stock terms By Investing.com - Investing.com
Aytu BioPharma Shareholders Approve All Proposals at Annual Meeting By Investing.com - Investing.com UK
Analyst boosts PB Fintech stock target on strong 1Q operational trends By Investing.com - Investing.com UK
US$5.50: That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After Its Latest Results - Yahoo New Zealand News
Aytu BioPharma Shareholders Approve All Proposals at Annual Meeting - Investing.com
Massimo Group showcases new line at equipment show By Investing.com - Investing.com India
It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year - Simply Wall St
It's Unlikely That The CEO Of Aytu BioPharma, Inc. (NASDAQ:AYTU) Will See A Huge Pay Rise This Year - Yahoo Finance
Aytu Biopharma announces paydown and refinancing of term loan (NASDAQ:AYTU) - Seeking Alpha
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms - StockTitan
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms - AccessWire
Aytu BioPharma (NASDAQ:AYTU) Stock Crosses Below 50 Day Moving Average of $3.03 - Defense World
Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden - Simply Wall St
Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Expected To Breakeven In The Medium-Term - Yahoo Canada Shine On
Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 - Yahoo Canada Finance
Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 - Yahoo Finance
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Aytu BioPharma sees revenue growth, shifts focus to ADHD - Investing.com India
Aytu Biopharma Inc Stock (AYTU) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.23%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):